




RealRate

PHARMACEUTICAL 2012

Respirerx Pharmaceuticals Inc
Rank 143 of 196



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Respirerx Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Respirerx Pharmaceuticals Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Respirerx Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 96% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	1,745
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,145
Liabilities, Non-Current	0
Other Assets	8.9
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	6.9
Other Revenues	3,115
Property and Equipment	67
Research and Development	2,188
Selling, General and Administrative Expense	3,189

Output Variable	Value in 1000 USD
Assets	1,821
Liabilities	1,145
Expenses	5,376
Revenues	3,115
Stockholders Equity	676
Net Income	-2,255
Comprehensive Net Income	-2,255
BaseVar	5,732
ECR before LimitedLiability	-53%
Economic Capital Ratio	138%